NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00950300,A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer,https://clinicaltrials.gov/study/NCT00950300,,COMPLETED,"In this open-label multicenter trial, participants with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil, epirubicin, and cyclophosphamide) concurrent with either SC Herceptin or IV Herceptin. After surgery, participants will receive a further 10 cycles of SC or IV Herceptin as per randomization to complete 1 year of treatment. All cycles will be 21 days in length. After the end of study treatment, participants will be followed for safety and efficacy for up to 5 years or until disease recurrence, whichever is earlier.",YES,Breast Cancer,DRUG: 5-Fluorouracil|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Herceptin IV [trastuzumab]|DRUG: Herceptin SC [trastuzumab],"Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery, Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (μg/mL)., Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)|Percentage of Participants With Pathological Complete Response (pCR), Participants were evaluated following eight cycles of treatment and after surgery to assess for pCR, defined as absence of neoplastic invasive cells in the breast according to pathologist examination. The percentage of participants with pCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method., After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)","Observed Ctrough of Trastuzumab After Surgery, Pre-dose samples were obtained after surgery (Cycle 13). The observed Ctrough was recorded, averaged among all participants, and expressed in μg/mL., Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)|Predicted Ctrough of Trastuzumab Prior to Surgery, Predicted Ctrough at pre-dose prior to surgery (Cycle 8) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL., Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)|Predicted Ctrough of Trastuzumab After Surgery, Predicted Ctrough at pre-dose after surgery (Cycle 13) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL., Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)|Number of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery, Pre-dose samples were obtained prior to surgery (Cycle 8). The number of participants who had an observed Ctrough \>20 μg/mL was reported., Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)|Number of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery, Pre-dose samples were obtained after surgery (Cycle 13). The number of participants who had an observed Ctrough \>20 μg/mL was reported., Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)|Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery, PK samples were obtained prior to surgery (Cycle 7). The Cmax during Cycle 7 was recorded, averaged among all participants, and expressed in μg/mL., Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)|Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery, PK samples were obtained prior to surgery (Cycle 7). The Tmax during Cycle 7 was recorded, averaged among all participants, and expressed in days., Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)|Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery, PK samples were obtained prior to surgery (Cycle 7). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 7 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in days multiplied by micrograms per milliliters (d\*μg/mL)., Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)|Cmax of Trastuzumab After Surgery, PK samples were obtained after surgery (Cycle 12). The Cmax during Cycle 12 was recorded, averaged among all participants, and expressed in μg/mL., Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)|Tmax of Trastuzumab After Surgery, PK samples were obtained after surgery (Cycle 12). The Tmax during Cycle 12 was recorded, averaged among all participants, and expressed in days., Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)|AUC21d of Trastuzumab After Surgery, PK samples were obtained after surgery (Cycle 12). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 12 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in d\*μg/mL., Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)|Percentage of Participants With Total Pathological Complete Response (tpCR), Participants were evaluated following eight cycles of treatment and after surgery to assess for tpCR, defined as absence of neoplastic invasive cells in the breast and axillary lymph nodes according to pathologist examination. The percentage of participants with tpCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method., After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)|Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline, Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to less than (\<) 10 millimeters (mm) with no prior assessment of progressive disease (PD). PR was defined as greater than or equal to (≥) 30% decrease from Baseline in sum diameter (SD) of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. The percentage of participants with overall response of CR or PR at the end of neoadjuvant treatment was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method., Tumor assessments at Baseline; on Day 1 of Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months overall)|Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline, Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to \<10 mm with no prior assessment of PD. PR was defined as ≥30% decrease from Baseline in SD of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. Time to response was defined as the time from first dose of study medication to the first assessment of CR or PR, which was the date the response was first documented by objective evidence, among participants with an overall response of CR or PR., Tumor assessments at Baseline; on Day 1 Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of chemotherapy (approximately 6 months overall)|Percentage of Participants Who Experienced a Protocol-Defined Event, Protocol-defined events included disease recurrence/progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. The percentage of participants who experienced a protocol-defined event at any time during the study was reported., Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)|Event-Free Survival (EFS), Protocol-defined events included disease recurrence or progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. EFS was estimated by Kaplan-Meier analysis and defined as the time from randomization to the first protocol-defined event., Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)|Percentage of Participants Who Died, The percentage of participants who died at any time during the study was reported., Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)|Overall Survival (OS), OS was estimated by Kaplan-Meier analysis and defined as the time from randomization to death from any cause., Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)|Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab, Participants provided PK samples for evaluation of anti-trastuzumab antibodies. The number of participants with ""Treatment-induced ADAs"" and ""Treatment-enhanced ADA"" against trastuzumab at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer)., Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18|Number of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20), Participants in the Herceptin SC arm provided PK samples for evaluation of anti-rHuPH20 antibodies. The number of participants with ""Treatment-induced ADAs"" and ""Treatment-enhanced ADA"" against rHuPH20 (an excipient unique to the SC formulation) at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer)., Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18",,Hoffmann-La Roche,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,596,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BO22227|2008-007326-19,2009-10-16,2011-07-12,2017-01-24,2009-07-31,2017-01-23,2018-01-23,"Centro Medico San Roque; Oncology Dept, Tucuman, T4000IAK, Argentina|Caipo; Oncology, Tucuman, T400IAK, Argentina|Hospital Sao Rafael - HSR, Salvador, BA, 41253-190, Brazil|Hospital das Clinicas - UFPR; Quimioterapia, Curitiba, PR, 80060-900, Brazil|Liga Norte Riograndense Contra O Câncer, Natal, RN, 59040150, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, 88301-220, Brazil|Hospital Amaral Carvalho, Jau, SP, 17210-080, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, 01246-000, Brazil|Hospital Perola Byington, Sao Paulo, SP, 01317-000, Brazil|Instituto de Oncologia de Sorocaba - CEPOS, Sorocaba, SP, 18030-245, Brazil|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, H1T 2M4, Canada|CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY, Quebec, G1S 4L8, Canada|Hospital Universitario San Ignacio, Bogota, 000472, Colombia|Grupo Salud Coop, Bogota, Colombia|Oncólogos de Occidente, Pereira, 600004, Colombia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, 779 00, Czechia|Krajska Nemocnice Pardubice Neurologicka Klinika, Pardubice, 532 03, Czechia|Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni, Praha, 140 59, Czechia|Lekarske Fakulty Univerzity Karlovy Fakultni Nemocnice Na Bulovce; Ustav Radiacni Onkologie, Praha, 180 81, Czechia|North Estonia Medical Centre Foundation; Oncology Centre, Tallinn, 13419, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, 50406, Estonia|HOPITAL JEAN MINJOZ; Oncologie, Besancon, 25030, France|Institut Daniel Hollard; Chimiotherapie Ambulatoire, Grenoble, 38000, France|Hopital Albert Michallon; Oncologie, La Tronche, 38700, France|Centre Jean Bernard, Le Mans, 72015, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, 75475, France|Institut Jean Godinot; Hopital De Jour, Reims, 51056, France|Centre Rene Huguenin; Medecine B, St Cloud, 92210, France|CAMPUS CHARITÉ MITTE; Tagesklinik für Onkologie u.Hämatologie, Berlin, 10117, Germany|Praxis Dr. Schoenegg, Berlin, 10719, Germany|Johanniter GmbH; Johanniter-Krankenhaus; Internistische Onkologie, Bonn, 53113, Germany|St. Johannes Hospital, Dortmund, 44137, Germany|Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding, Hannover, 30177, Germany|Sankt Elisabeth Krankenhaus; Gynaekology, Leipzig, 04277, Germany|Klinik Lippe Lemgo; Frauenklinik, Lemgo, 32657, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, 63069, Germany|Klinik Obergöltzsch; Abt. Gynäkologie, Rodewisch, 08228, Germany|Universitätsklinik Tübingen; Frauenklinik, Tübingen, 72076, Germany|Centro Oncologico S.A., Guatemala, 01010, Guatemala|Queen Mary Hospital; Surgery, Hong Kong, 852, Hong Kong|Semmelweis Egyetem Onkologiai Központ, Budapest, 1083, Hungary|Hospital of Aladar Petz; Dept of Oncoradiology, Gyor, 9023, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, 6720, Hungary|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, 9112001, Israel|Rabin Medical Center; Oncology Dept, Petach Tikva, 49100, Israel|Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica, Napoli, Campania, 80131, Italy|ASST DI CREMONA; Dip. Medicina - S.C. Oncologia, Cremona, Lombardia, 26100, Italy|Fondazione Salvatore Maugeri; Servizio Di Prevenzione Oncologica, Pavia, Lombardia, 27100, Italy|Fondazione Salvatore Maugeri, Pavia, Lombardia, 27100, Italy|Gachon Medical School Gil Medical Center; Medical Oncology, Incheon, 405-760, Korea, Republic of|Samsung Medical Centre; Division of Hematology/Oncology, Seoul, 135-710, Korea, Republic of|Korea University Anam Hospital; Oncology Haemotology, Seoul, 136-705, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, 138-736, Korea, Republic of|Hospital Privado San Jose; Oncologia, Obregon, 85000, Mexico|Centro Oncológico Estatal; ISSSEMYM Oncología, Toluca, 50180, Mexico|Centro Oncologico America, Panama, 0834-02723, Panama|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, 04001, Peru|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, 11, Peru|Oncosalud Sac; Oncología, Lima, 41, Peru|Unidad de Investigacion Oncologia Clinica - Piura; Unidad de Oncología Clínica, Piura, 20011, Peru|Clinica Ricardo Palma, San Isidro, Lima 27, Peru|Wojewodzki Szpital Zespolony; Oddział Onkologii, Elblag, 82-300, Poland|COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin, 20-090, Poland|Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o., Olsztyn, 10-513, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warszawa, 02-781, Poland|FSBI""National Medical Research Center of Oncology named after N.N.Petrov"" MHRF, St Petersburg, Leningrad, 197758, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, 153040, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, 115478, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, 143423, Russian Federation|State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary, Pyatigorsk, 357502, Russian Federation|SBI for HPE ""Ryazan State Medical University n.a. I.P. Pavlov"" of MoH of RF, Ryazan, 390011, Russian Federation|SBI of Healthcare Samara Regional Clinical Oncology Dispensary, Samara, 443031, Russian Federation|Saratov Regional Clinical Hospital & Pathology Centre, Saratov, 410053, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, 197022, Russian Federation|SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, 355045, Russian Federation|Tula Regional Oncology Dispensary, Tula, 300053, Russian Federation|GUZ Vladimir Regional Clinical Oncological Dispensary, Vladimir, 600009, Russian Federation|Vychodoslovensky onkologicky ustav, Kosice, 04001, Slovakia|Nzz - Oncology Outpatient Clinic, Poprad, 05801, Slovakia|National Hospital; Oncotherapy Dept, Bloemfontein, 9301, South Africa|Cancercare, Cape Town, 7506, South Africa|Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept, Cape Town, 7506, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, 2193, South Africa|Pretoria-East Hospital; 1 Sanwood Park, Pretoria, 0081, South Africa|Rondebosch Oncology Centre, Rondebosch, 7700, South Africa|Sandton Oncology Centre, Sandton, 2196, South Africa|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, 15706, Spain|Hospital Universitari Sant Joan de Reus; Servicio de Oncologia, Reus, Tarragona, 43204, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, 28007, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, 46010, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, 50009, Spain|Skånes University Hospital, Skånes Department of Onclology, Lund, 22185, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, 75185, Sweden|Changhua Christian Hospital; Dept of Surgery, Changhua, 500, Taiwan|Taipei Veterans General Hospital, Taipei City, 112, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, 112, Taiwan|Chang Gung Medical Foundation-Taipei, Taoyuan, 333, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, 10330, Thailand|National Cancer Inst., Bangkok, 10400, Thailand|Phramongkutklao Hospital;Dept Surgery/Surgical Oncology Unit, Bangkok, 10400, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, 10700, Thailand|Prince of Songkla Uni ; Unit of Medical Oncology, Songkhla, 90110, Thailand|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, 07070, Turkey|Istanbul Uni of Medicine Faculty; Oncology Dept, Istanbul, 34390, Turkey|Dokuz Eylul Uni Medical Faculty; Oncology Dept, Izmir, 35340, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, Ankara, 06100, Turkey",
